Rajeev Saggar Sells 21,142 Shares of Liquidia (NASDAQ:LQDA) Stock

Liquidia Corporation (NASDAQ:LQDA) insider Rajeev Saggar sold 21,142 shares of Liquidia stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $37.43, for a total value of $791,345.06. Following the completion of the transaction, the insider directly owned 176,883 shares in the company, valued at $6,620,730.69. This represents a 10.68% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Rajeev Saggar also recently made the following trade(s):

• On Wednesday, November 5th, Rajeev Saggar sold 71,381 shares of Liquidia stock. The shares were sold at an average price of $27.00, for a total transaction of $1,927,287.00.

Liquidia Trading Up 4.1%

LQDA traded up $1.49 during trading on Tuesday, hitting $38.09. 2,055,159 shares of the company’s stock were exchanged, compared to its average volume of 2,814,845. Liquidia Corporation has a 1 year low of $11.26 and a 1 year high of $39.29. The stock has a 50 day moving average price of $31.94 and a 200 day moving average price of $25.40. The firm has a market cap of $3.31 billion, a P/E ratio of -26.45, a price-to-earnings-growth ratio of 1.19 and a beta of 0.48. The company has a current ratio of 2.20, a quick ratio of 1.96 and a debt-to-equity ratio of 6.19.

Liquidia (NASDAQ:LQDA) last posted its earnings results on Monday, November 3rd. The company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.41. Liquidia had a negative net margin of 176.04% and a negative return on equity of 296.78%. The business had revenue of $54.34 million for the quarter, compared to analyst estimates of $18.86 million. The business’s revenue was up 1106.7% compared to the same quarter last year. As a group, analysts expect that Liquidia Corporation will post -1.51 EPS for the current fiscal year.

More Liquidia News

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Short interest fell materially in December — short interest declined 18.1% to 10,709,682 shares as of Dec. 31 (about 17.6% of shares were sold short) and the days-to-cover was ~11.6. Fewer active shorts can reduce downside pressure and may have contributed to the stock moving higher. (Market data entry)
• Neutral Sentiment: January short-interest data shows 0 shares as of Jan. 12 — this is almost certainly a reporting or data glitch rather than a real liquidation of all short positions. Investors should monitor the next short-interest report for a corrected figure. (Market data entry)
• Negative Sentiment: CEO Roger Jeffs sold 66,610 shares at an average $37.43 (≈$2.49M); his stake decreased ~6.03%. This large insider sale may be seen as a negative signal by some investors. SEC Filing
• Negative Sentiment: CFO Michael Kaseta sold 36,932 shares at $37.43 (≈$1.38M); his holding fell ~9.52%. SEC Filing
• Negative Sentiment: General Counsel Russell Schundler sold 27,289 shares at $37.43 (≈$1.02M); his holding fell ~4.50%. SEC Filing
• Negative Sentiment: Other insiders (including Rajeev Saggar, Jason Adair, Scott Moomaw, Sarah Krepp, CAO Dana Boyle) also executed sales on Jan. 12 at ~$37.43 per share, each reducing positions between ~6–11.7%. These combined sales represent significant insider liquidity taken at current prices. Rajeev Saggar SEC Filing Dana Boyle SEC Filing Jason Adair SEC Filing Scott Moomaw SEC Filing Sarah Krepp SEC Filing

Analyst Upgrades and Downgrades

LQDA has been the topic of several analyst reports. Jefferies Financial Group raised their target price on Liquidia from $45.00 to $55.00 and gave the company a “buy” rating in a report on Tuesday. HC Wainwright boosted their target price on shares of Liquidia from $35.00 to $50.00 and gave the stock a “buy” rating in a research report on Tuesday, November 4th. Raymond James Financial restated a “strong-buy” rating and issued a $47.00 target price on shares of Liquidia in a research note on Tuesday, November 4th. BTIG Research reaffirmed a “buy” rating and set a $49.00 price target on shares of Liquidia in a research note on Friday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Liquidia in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Liquidia presently has an average rating of “Moderate Buy” and an average target price of $39.67.

Institutional Trading of Liquidia

Several institutional investors have recently added to or reduced their stakes in the stock. Farallon Capital Management LLC boosted its stake in Liquidia by 102.1% during the 3rd quarter. Farallon Capital Management LLC now owns 8,565,638 shares of the company’s stock valued at $194,783,000 after acquiring an additional 4,326,876 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Liquidia by 10.2% in the 3rd quarter. Vanguard Group Inc. now owns 3,961,217 shares of the company’s stock valued at $90,078,000 after purchasing an additional 367,659 shares in the last quarter. Opaleye Management Inc. lifted its position in shares of Liquidia by 9.5% during the second quarter. Opaleye Management Inc. now owns 2,475,000 shares of the company’s stock worth $30,838,000 after purchasing an additional 215,000 shares during the last quarter. TCG Crossover Management LLC bought a new position in shares of Liquidia during the third quarter worth about $38,887,000. Finally, Caprock Group LLC acquired a new position in Liquidia in the third quarter worth about $37,114,000. 64.54% of the stock is owned by institutional investors and hedge funds.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).